NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
93.66
+0.18 (+0.19%)
At close: 4:02PM EDT

93.66 0.00 (0.00%)
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Previous Close93.48
Open93.44
Bid90.50 x 800
Ask93.88 x 800
Day's Range93.36 - 93.84
52 Week Range72.30 - 93.89
Volume3,730,803
Avg. Volume1,950,671
Market Cap217.104B
Beta (3Y Monthly)0.64
PE Ratio (TTM)17.41
EPS (TTM)5.38
Earnings DateN/A
Forward Dividend & Yield2.83 (3.03%)
Ex-Dividend Date2019-03-04
1y Target Est104.00
Trade prices are not sourced from all markets
  • Is Biogen a Bad-News Buy Now?
    Motley Fool5 hours ago

    Is Biogen a Bad-News Buy Now?

    Now that the riskiest asset in biotech is off the table, it's time to reconsider an industry legend that's down 30% on Thursday.

  • Cooper Companies' (COO) CooperVision Gains Momentum Globally
    Zacks12 hours ago

    Cooper Companies' (COO) CooperVision Gains Momentum Globally

    Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

  • Major biotech landlord plants flag in East Bay with acquisition of Novartis site
    American City Business Journalsyesterday

    Major biotech landlord plants flag in East Bay with acquisition of Novartis site

    As it builds out high-profile biotech developments on the Peninsula, BioMed Realty is digging into the East Bay in a big way. The San Diego-based unit of Blackstone Group LP (NYSE: BX) paid about $135 million for the six-story, 250,000-square-foot structure, the company said Wednesday, which includes an adjacent space for as much as 850,000 square feet of additional lab and office space. "We plan to offer in excess of 1 million square feet of space to innovative tenants, including biotech and other laboratory users," Denis Sullivan, executive vice president and chief investment officer for BioMed, said in a statement.

  • Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
    Zacksyesterday

    Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

    The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

  • Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
    Zacksyesterday

    Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

    Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

  • Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs
    Zacks2 days ago

    Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs

    Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.

  • 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?
    Motley Fool3 days ago

    3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

    Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

  • Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 days ago

    Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript

    TLRY earnings call for the period ending December 31, 2018.

  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zacks3 days ago

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks3 days ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • Roche Gets Approval for Label Expansion of MabThera in Europe
    Zacks6 days ago

    Roche Gets Approval for Label Expansion of MabThera in Europe

    Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

  • Benzinga7 days ago

    The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...

  • Roche Receives EC Approval for Label Expansion of Hemlibra
    Zacks7 days ago

    Roche Receives EC Approval for Label Expansion of Hemlibra

    Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

  • Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades
    Investopedia8 days ago

    Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades

    Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.

  • Novartis generics boss quits amid conjecture over business's future
    Reuters8 days ago

    Novartis generics boss quits amid conjecture over business's future

    Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.

  • Financial Times8 days ago

    [$$] Head of Novartis generic drugs business steps down

    The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.

  • The Wall Street Journal9 days ago

    [$$] Novartis, Volkswagen Focus on Improving Culture Following Compliance Setbacks

    The chief compliance officer, once responsible for simply making sure companies stayed within legal bounds, is now responsible for a broader range of priorities. Among them: guarding a company’s reputation, ensuring investors and government agencies have the information they need, and strengthening internal culture around compliance efforts, executives said Tuesday during a panel discussion hosted by Dow Jones Risk & Compliance and The Wall Street Journal.

  • How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
    Investor's Business Daily9 days ago

    How This Looming Patent Battle Could Challenge Bristol-Celgene Deal

    Celgene and Novartis could go head-to-head in a patent battle over multiple sclerosis treatment ozanimod, an analyst said Tuesday. Novartis has a key patent for the S1P modulator drug class.

  • Allergan Announces FDA Acceptance of Migraine Candidate NDA
    Zacks9 days ago

    Allergan Announces FDA Acceptance of Migraine Candidate NDA

    Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

  • Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
    Zacks9 days ago

    Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer

    Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.

  • Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
    Zacks10 days ago

    Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus

    Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

  • 10 Stocks For The Gene Therapy Revolution
    Investopedia11 days ago

    10 Stocks For The Gene Therapy Revolution

    Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.

  • Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
    Zacks13 days ago

    Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

    Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

  • How Novartis Is Transforming Its Structure in 2019
    Market Realist14 days ago

    How Novartis Is Transforming Its Structure in 2019

    How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Business transformation Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company. According to the company’s

  • Dutch join backlash at expensive drugs by making their own
    Reuters14 days ago

    Dutch join backlash at expensive drugs by making their own

    In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate, an intravenous treatment for certain types of cancer. Drug firm Novartis, which in 2018 acquired rights to sell it in Europe, is asking more than five times that for its proprietary version, Lutathera. Thomasa is part of a protest against high drug prices launched by an unlikely group of rebels: Dutch pharmacies.